Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 244

1.

Intracellular Galectin-9 Controls Dendritic Cell Function by Maintaining Plasma Membrane Rigidity.

Querol Cano L, Tagit O, Dolen Y, van Duffelen A, Dieltjes S, Buschow SI, Niki T, Hirashima M, Joosten B, van den Dries K, Cambi A, Figdor CG, van Spriel AB.

iScience. 2019 Dec 20;22:240-255. doi: 10.1016/j.isci.2019.11.019. Epub 2019 Nov 15.

2.

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.

Westdorp H, Creemers JHA, van Oort IM, Schreibelt G, Gorris MAJ, Mehra N, Simons M, de Goede AL, van Rossum MM, Croockewit AJ, Figdor CG, Witjes JA, Aarntzen EHJG, Mus RDM, Brüning M, Petry K, Gotthardt M, Barentsz JO, de Vries IJM, Gerritsen WR.

J Immunother Cancer. 2019 Nov 14;7(1):302. doi: 10.1186/s40425-019-0787-6.

3.

Microfluidics-Assisted Size Tuning and Biological Evaluation of PLGA Particles.

Operti MC, Dölen Y, Keulen J, van Dinther EAW, Figdor CG, Tagit O.

Pharmaceutics. 2019 Nov 8;11(11). pii: E590. doi: 10.3390/pharmaceutics11110590.

4.

Imaging of T-cells and their responses during anti-cancer immunotherapy.

Krekorian M, Fruhwirth GO, Srinivas M, Figdor CG, Heskamp S, Witney TH, Aarntzen EHJG.

Theranostics. 2019 Oct 16;9(25):7924-7947. doi: 10.7150/thno.37924.

5.

Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering.

van der Schoot JMS, Fennemann FL, Valente M, Dolen Y, Hagemans IM, Becker AMD, Le Gall CM, van Dalen D, Cevirgel A, van Bruggen JAC, Engelfriet M, Caval T, Bentlage AEH, Fransen MF, Nederend M, Leusen JHW, Heck AJR, Vidarsson G, Figdor CG, Verdoes M, Scheeren FA.

Sci Adv. 2019 Aug 28;5(8):eaaw1822. doi: 10.1126/sciadv.aaw1822. eCollection 2019 Aug.

6.

Synthetic Semiflexible and Bioactive Brushes.

Voerman D, Schluck M, Weiden J, Joosten B, Eggermont LJ, van den Eijnde T, Ignacio B, Cambi A, Figdor CG, Kouwer PHJ, Verdoes M, Hammink R, Rowan AE.

Biomacromolecules. 2019 Jul 8;20(7):2587-2597. doi: 10.1021/acs.biomac.9b00385. Epub 2019 Jun 13.

7.

Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells.

Schluck M, Hammink R, Figdor CG, Verdoes M, Weiden J.

Front Immunol. 2019 May 3;10:931. doi: 10.3389/fimmu.2019.00931. eCollection 2019.

8.

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.

Cruz LJ, Tacken PJ, van der Schoot JMS, Rueda F, Torensma R, Figdor CG.

Molecules. 2019 May 12;24(9). pii: E1825. doi: 10.3390/molecules24091825.

9.

Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity.

Fennemann FL, de Vries IJM, Figdor CG, Verdoes M.

Front Immunol. 2019 Apr 16;10:824. doi: 10.3389/fimmu.2019.00824. eCollection 2019.

10.

Injectable Biomimetic Hydrogels as Tools for Efficient T Cell Expansion and Delivery.

Weiden J, Voerman D, Dölen Y, Das RK, van Duffelen A, Hammink R, Eggermont LJ, Rowan AE, Tel J, Figdor CG.

Front Immunol. 2018 Nov 28;9:2798. doi: 10.3389/fimmu.2018.02798. eCollection 2018.

11.

Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells.

Meddens MBM, Mennens SFB, Celikkol FB, Te Riet J, Kanger JS, Joosten B, Witsenburg JJ, Brock R, Figdor CG, Cambi A.

Front Immunol. 2018 Oct 9;9:2333. doi: 10.3389/fimmu.2018.02333. eCollection 2018.

12.

C-type lectin-like receptor 2 (CLEC-2)-dependent dendritic cell migration is controlled by tetraspanin CD37.

de Winde CM, Matthews AL, van Deventer S, van der Schaaf A, Tomlinson ND, Jansen E, Eble JA, Nieswandt B, McGettrick HM, Figdor CG, Tomlinson MG, Acton SE, van Spriel AB.

J Cell Sci. 2018 Oct 2;131(19). pii: jcs214551. doi: 10.1242/jcs.214551.

13.

A comparative assessment of continuous production techniques to generate sub-micron size PLGA particles.

Operti MC, Fecher D, van Dinther EAW, Grimm S, Jaber R, Figdor CG, Tagit O.

Int J Pharm. 2018 Oct 25;550(1-2):140-148. doi: 10.1016/j.ijpharm.2018.08.044. Epub 2018 Aug 23.

PMID:
30144511
14.

Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells.

Wimmers F, Subedi N, van Buuringen N, Heister D, Vivié J, Beeren-Reinieren I, Woestenenk R, Dolstra H, Piruska A, Jacobs JFM, van Oudenaarden A, Figdor CG, Huck WTS, de Vries IJM, Tel J.

Nat Commun. 2018 Aug 20;9(1):3317. doi: 10.1038/s41467-018-05784-3.

15.

Dendritic cells in cancer immunotherapy.

Le Gall CM, Weiden J, Eggermont LJ, Figdor CG.

Nat Mater. 2018 Jun;17(6):474-475. doi: 10.1038/s41563-018-0093-6. No abstract available.

PMID:
29795222
16.

Endolysosomal-Escape Nanovaccines through Adjuvant-Induced Tumor Antigen Assembly for Enhanced Effector CD8+ T Cell Activation.

Qiu L, Valente M, Dolen Y, Jäger E, Beest MT, Zheng L, Figdor CG, Verdoes M.

Small. 2018 Apr;14(15):e1703539. doi: 10.1002/smll.201703539. Epub 2018 Mar 1.

PMID:
29493121
17.

Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.

Gorris MAJ, Halilovic A, Rabold K, van Duffelen A, Wickramasinghe IN, Verweij D, Wortel IMN, Textor JC, de Vries IJM, Figdor CG.

J Immunol. 2018 Jan 1;200(1):347-354. doi: 10.4049/jimmunol.1701262. Epub 2017 Nov 15.

18.

Migrating into the Tumor: a Roadmap for T Cells.

van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJM.

Trends Cancer. 2017 Nov;3(11):797-808. doi: 10.1016/j.trecan.2017.09.006. Epub 2017 Nov 6. Review.

PMID:
29120755
19.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG.

Oncotarget. 2017 Jun 27;8(40):67439-67456. doi: 10.18632/oncotarget.18698. eCollection 2017 Sep 15.

20.

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.

Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, de Haas N, Verweij D, Van Herpen CML, Kaanders JH, van Krieken JHJM, Van Laarhoven HWM, Hooijer GKJ, Punt CJA, Asai A, de Vries IJM, Lesterhuis WJ.

Oncotarget. 2017 May 7;8(33):54434-54443. doi: 10.18632/oncotarget.17661. eCollection 2017 Aug 15.

Supplemental Content

Loading ...
Support Center